March 2021 U.S. Federal Funding Opportunities

Description

U.S. Federal Funding Opportunities (FFO) is a monthly resource that summarizes awards, grants, and fellowship opportunities issued by the U.S. government related to research, evaluation and dissemination. These funding opportunities are relevant to the field of child development and, more broadly, behavioral and social science research.

Materials
Components
Text

Highlights -

The March 2021 FFO lists over 100 funding opportunities for research, evaluation, and dissemination, including multiple highlighted funding opportunities.

(1) A Centers for Disease Control and Prevention (CDC) funding opportunity to support investigator-initiated research proposals to rigorously evaluate approaches (programs, policies, or practices) for their impact on primary prevention of child sexual abuse (CSA) perpetrated by youth or adults. Applications are due by May 10, 2021.

(2) A National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) funding opportunity to support research and related activities toward services, technologies, and other interventions to support parents with disabilities in their parenting roles. Applications are due by May 7, 2021.

(3) A National Institutes of Health (NIH) funding opportunity to support the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, including the National Youth Tobacco Survey (NYTS), to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Applications are due by October 8, 2021.

(4) A National Institute of Mental Health (NIMH) funding opportunity to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Applications are due by June 15, 2021.